RUNX3 and EOMES, but not T-bet expression was decreased in blood CD8+ memory T cells in the treatment-naive MS group versus the HC group (p < 0.01 and p < 0.001); this was not seen in the NTZ-MS cohort (p < 0.05, Figure 1A). This evidence concerns the gene CD8A and myeloid sarcoma.